Get the Stockscreener App
3.98
2.84%
0.11
After Hours:
4.05
0.07
+1.76%
Perspective Therapeutics Inc stock is traded at $3.98, with a volume of 1.72M.
It is up +2.84% in the last 24 hours and down -15.50% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.87
Open:
$3.93
24h Volume:
1.72M
Relative Volume:
1.14
Market Cap:
$453.90M
Revenue:
$884.00K
Net Income/Loss:
$-103.64M
P/E Ratio:
-2.8543
EPS:
-1.3944
Net Cash Flow:
$-95.45M
1W Performance:
+3.38%
1M Performance:
-15.50%
6M Performance:
+90.43%
1Y Performance:
+58.57%
1-Day Range:
$3.905
$4.105
1-Week Range:
$3.585
$4.105
52-Week Range:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.98 | 441.36M | 884.00K | -103.64M | -95.45M | -1.3944 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $8 to $15 - Moomoo
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - Moomoo
Piper Sandler Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Perspective Therapeutics Presents Positive Clinical Data for [212Pb] Radiopharmaceuticals in Melanoma, Neuroendocrine, and Solid Tumors at ASCO 2026 - Minichart
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO - Stock Titan
Perspective Therapeutics, Inc. Reports Positive Updates on Clinical Programs at ASCO 2026, Highlighting Efficacy and Safety of [212Pb]VMT-α-NET, [212Pb]VMT01, and [212Pb]PSV359 - Quiver Quantitative
Early melanoma trial sees tumor responses in hard-to-treat patients - Stock Titan
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation - MSN
Perspective Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Earnings Preview: CATX to Report Financial Results Post-market on May 11 - Moomoo
CATX: VMT-α-NET shows high efficacy and safety, with phase III readiness and broad pipeline progress - TradingView
CATX News | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Perspective Therapeutics doses first patients in two trial cohorts By Investing.com - Investing.com Australia
Perspective Therapeutics doses first patients in two trial cohorts - Investing.com UK
Perspective Therapeutics (CATX) Begins Patient Dosing in New Cli - GuruFocus
Perspective Therapeutics Doses First Patients for New Cohorts of Two Phase 1/2a Studies in Tumors - marketscreener.com
Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors - Quiver Quantitative
Two cancer radiopharmaceuticals start dosing patients in early trials - Stock Titan
CATX Should I Buy - Intellectia AI
Analysts Are Bullish on These Healthcare Stocks: SI-Bone (SIBN), Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX) - Stock Titan
RBC Capital reiterates Outperform on Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
RBC Capital reiterates Outperform on Perspective Therapeutics stock - Investing.com
MSN Money - MSN
Working capital per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics earnings beat by $0.05, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics (NYSEARCA:CATX) Posts Mixed Q1 2026 Results, EPS Beat and Revenue Miss - ChartMill
Perspective Therapeutics 1Q Loss/Shr 25c >CATX - Moomoo
Is Perspective Therapeutics (CATX) Attractively Valued After Q1 - GuruFocus
Perspective Therapeutics: Q1 Earnings Snapshot - WKYC
Perspective Therapeutics Highlights Q1 Progress and Strengthened Finances - TipRanks
Perspective Therapeutics Q1 net loss widens as grant revenue drops - TradingView
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results - The Manila Times
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027 - Stock Titan
Perspective Therapeutics: $271M cash to advance 3 cancer trials - Stock Titan
Number of shareholders of Perspective Therapeutics, Inc. – AMEX:CATX - TradingView
Number of shareholders of Perspective Therapeutics, Inc. – DUS:AAJ0 - TradingView
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Transcript : Perspective Therapeutics, Inc.Shareholder/Analyst Call - marketscreener.com
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler - The Globe and Mail
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $14 - 富途牛牛
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics Advances 212Pb Radioligand Therapy for Targeted Oncology with Regional Manufacturing and Theranostic Approach 1245 - Minichart
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Cap:
|
Volume (24h):